Lumida
/ALHC
⌘K
Alignment Healthcare Inc

Alignment Healthcare Inc

ALHC
$13.43USD+2.05%+0.27 today

MARKET CAP

2.8B

P/E (TTM)

149.2x

FWD P/E

DAY RANGE

$13 – $14

52W RANGE

$13
$25

AI Summary

Stalk
Sell NowMedium

ALHC remains in a Stage 4 decline with supply firmly in control, evidenced by sequential lower highs and lower lows under declining 9- and 20-day EMAs. Price is oversold and continues to be rejected at these EMAs, reinforcing a bearish medium-term bias. Short-term timing favors sellers as rallies toward the falling EMAs fail. Execution is authorized on rallies back into the 9/20 EMAs, while sustained acceptance above the 20-day EMA would invalidate the current bearish posture.

  • Q2 membership reached 294,100 (+31% YoY) and revenue hit $1.3B (+32% YoY)
  • Adjusted EBITDA rose to $68M (+48% YoY) with a 5.1% margin
  • Negative earnings yield and low profitability raise valuation concerns
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Alignment Healthcare (NASDAQ: ALHC) is a leading player in the Medicare Advantage sector, specializing in providing innovative, technology-enabled health plans. The company focuses on delivering high-quality care to seniors through its Care Anywhere clinical model and advanced analytics, ensuring effective management of complex health needs. With a strong momentum in membership growth, a rising focus on operational efficiencies, and an ambitious trajectory towards broader market penetration, Alignment Healthcare is well-positioned in a rapidly evolving healthcare landscape.

Bull says

  • Q2 membership reached 294,100 (+31% YoY) and revenue hit $1.3B (+32% YoY)
  • Adjusted EBITDA rose to $68M (+48% YoY) with a 5.1% margin
  • Claims automation improved from <15% to >60% via AI-driven processes
  • Analyst upgrades to ‘buy’ and higher price targets suggest upside
  • <4% market share outside California offers significant expansion runway
  • Strong growth, momentum, liquidity and quality factors support valuation

Bear says

  • Negative earnings yield and low profitability raise valuation concerns
  • Regulatory shifts in Medicare Advantage may cut reimbursement rates
  • High short interest and low institutional ownership signal investor skepticism
  • Rapid membership scaling risks execution strain and potential churn
  • Anticipated 2027 rate cuts could compress margins further
  • Weak profitability and dividend yield factors weigh on stock outlook

Investment themes with ALHC

Health Care Providers -0.61%

UNH · CVS · HCA

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-15-2026bullish

Transcript signals

Bull points

  • we have the benefit of setting up our data architecture with a clean slate, which has given us the kind of visibility and control we have. When you have that, you don't need the amount of FTEs, and I think the secret sauce is how the clinical, the operations, and the financial parts of the organization all seamlessly are operationalized from a workflow point of view.
  • evolving our machine learning algorithms and applying those AI techniques into the next generation of AI. I think that will give us better and faster insights that we can take action faster and I think the reason we're doing so well now is that the whole funding structure is changing.
  • manage the risk while maintaining high star ratings

Bear points

  • I think thematically you're seeing a lot of margin pressure down at the value-based care kind of provider, kind of global cap entity level.
  • we expect the 6 million of FG&amp;A timing favorability we experienced in the first half to reverse in the second half, leaving our full year FG&amp;A expectations roughly unchanged.
Read full transcript analysis ›